Ascend

Quality manufacturing capacity for developers of gene and cell therapies

First Investment: 2023

Biotech and pharmaceutical companies developing innovative gene and cell therapies no longer need to build an in-house capacity to manufacture these therapies. Ascend offers flexible chemistry, manufacturing, and controls (CMC) services for companies working in gene therapy, with an initial focus on Adeno-associated virus (AAV) vectors.

In The Media

Financial Times

UK biotech start-up raises $130mn to solve capacity bottleneck

Ascend

Explore Companies

Samsara Eco

Sparing the climate through infinite recycling of plastic waste

Nium

Making green ammonia for fertilizer and energy transport

Visolis

Using synthetic biology to manufacture carbon-negative materials

Nobell Foods

Plant-grown dairy cheese